Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Moutafi, M.K. (Myrto K.) | - |
| dc.creator | Molero, M. (Magdalena) | - |
| dc.creator | Martínez-Morilla, S. (Sandra) | - |
| dc.creator | Baena, J. (Javier) | - |
| dc.creator | Vathiotis, I.A. (Ioannis A.) | - |
| dc.creator | Gavrielatou, N. (Niki) | - |
| dc.creator | Castro-Labrador, L. (Laura) | - |
| dc.creator | Ruiz-de-Garibay, G. (Gorka) | - |
| dc.creator | Adradas, V. (Vera) | - |
| dc.creator | Orive-Mauleón, D. (Daniel) | - |
| dc.creator | Valencia, K. (Karmele) | - |
| dc.creator | Calvo-González, A. (Alfonso) | - |
| dc.creator | Montuenga-Badia, L.M. (Luis M.) | - |
| dc.creator | Ponce-Aix, S. (S.) | - |
| dc.creator | Schalper, K.A. (Kurt A.) | - |
| dc.creator | Herbst, R.S. (Roy S.) | - |
| dc.creator | Paz-Ares, L. (Luis) | - |
| dc.creator | Rimm, D.L. (David L.) | - |
| dc.creator | Zugazagoitia, J. (Jon) | - |
| dc.date.accessioned | 2023-01-05T08:57:41Z | - |
| dc.date.available | 2023-01-05T08:57:41Z | - |
| dc.date.issued | 2022 | - |
| dc.identifier.citation | Moutafi, M.K. (Myrto K.); Molero, M. (Magdalena); Martínez-Morilla, S. (Sandra); et al. "Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small- cell lung cancer". Journal for immunotherapy of cancer. 10 (8), 2022, e004757 | es |
| dc.identifier.issn | 2051-1426 | - |
| dc.identifier.uri | https://hdl.handle.net/10171/64953 | - |
| dc.description.abstract | Most patients with advanced non-small-cell lung cancer (NSCLC) fail to derive significant benefit from programmed cell death protein-1 (PD-1) axis blockade, and new biomarkers of response are needed. In this study, we aimed to discover and validate spatially resolved protein markers associated with sensitivity to PD-1 axis inhibition in NSCLC. | es_ES |
| dc.description.sponsorship | This work was supported by grants from the Lung Cancer Foundation of America (LCFA/IASLC/BMS research award), Spanish Association Against Cancer (AECC, LABAE2044), and Carlos III Health Institute (ISCIII, PI20/01494) to JZ, and Yale SPORE in Lung Cancer (P50 CA196530) to DLR and RSH. MKM is receiving a scholarship from the Hellenic Society of Medical Oncologists (HESMO). LMM is supported by FIMA, AECC Scientific Foundation (GCB14-2170), Fundación Ramón Areces, Spanish Ministry of Economy and Innovation, Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI19/00098), and Fundación Roberto Arnal Planelles. LP-A is supported by CIBERONC (CB16/12/00442). DLR is supported by the Yale SPORE in Lung Cancer (P50 CA196530) and has a sponsored research agreement from Konica/Minolta. JZ is supported by a Juan Rodes contract from the Carlos III Health Institute (JR19/00028). | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | BMJ | es_ES |
| dc.rights | info:eu-repo/semantics/openAccess | es_ES |
| dc.subject | Biomarkers, tumor | es_ES |
| dc.subject | Immunotherapy | es_ES |
| dc.subject | Lung neoplasms | es_ES |
| dc.subject | Programmed cell death 1 receptor | es_ES |
| dc.subject | Tumor microenvironment | es_ES |
| dc.title | Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small- cell lung cancer | es_ES |
| dc.type | info:eu-repo/semantics/article | es_ES |
| dc.description.note | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license | es_ES |
| dc.identifier.doi | 10.1136/jitc-2022-004757 | - |
| dadun.citation.number | 8 | es_ES |
| dadun.citation.publicationName | Journal for immunotherapy of cancer | es_ES |
| dadun.citation.startingPage | e004757 | es_ES |
| dadun.citation.volume | 10 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.
